CI-CSPC@EC2602B

HSBC Research Raises Stone Pharmaceutical's Target Price and Rating

SinoPharm Group Enters into a $18.5 Billion Collaboration

CLSA Raises Target Price for Stone Pharmaceutical Group to HKD 19

Stone Pharmaceutical Group Obtains Registration Approval for Chlorverine Liposomal Injection from National Medical Products Administration

CICC: Stone Pharmaceutical Authorizes AstraZeneca for 8 Innovative Drug Projects

China Renaissance Sees Potential in Stone Pharmaceutical and AstraZeneca Deal, but More Details are Needed

Jade Pharmaceutical Group Reaches R&D Agreement with AstraZeneca, but Stock Price Drops

CICC Reiterates Buy Rating on Stone Pharmaceutical Group While TipRanks Downgrades

Jade Pharmaceutical and AstraZeneca Sign $18.5 Billion Collaboration Agreement

AstraZeneca Prepaid $1.2 Billion to Stone Pharmaceutical Group

Jade Harbour Group Signs Strategic R&D Collaboration and Licensing Agreement with AstraZeneca for Long-acting Peptide Drugs

Stone Pharmaceutical's In-body CAR-T Product SYS6055 Approved for Clinical Trials by NMPA

NeoWis Holdings' Subsidiary Receives Clinical Trial Approval for SYS6090 Injection

Sino-pharm Innovation Anticipates Net Loss in 2025 and Increases R&D Investment

Sino-Pharm Group's New Drug SYH2072 Receives Clinical Trial Approval in US and China

Jade Pharmaceutical's Plaziquantel Metformin Extended-Release Tablets Submitted for Marketing Authorization

Stone Pharmaceutical's Empagliflozin Application for Market Approval Accepted

Stone Pharmaceutical's New Pulmonary Fibrosis Inhalation Drug Approved for Clinical Trials

Sino-Pharm Group Obtains Approval for Clinical Trials of Inhaled Nintedanib in China

Stone Pharmaceutical Group Secures Approval for Multiple Drug Trials in China

BOER POWER

KNOWLEDGE ATLAS

WAI CHUN GROUP

TOUYUN BIOTECH

TJCD

ASIA ENERGY LOG

HING LEE (HK)

TBKS HLDGS

HUAYUEXPRESSWAY

02513

01072

01093

01801

09992

01818

03986

09980

01880

03690

KNOWLEDGE ATLAS(02513) rose 14.81%, with a trading turnover 1.1 Billion HKD, and a year-to-date rose 173.5%. DONGFANG ELEC(01072) rose 7.11%, with a trading turnover 810.9 Million HKD, and a year-to-date rose 23%. ZHAOJIN MINING(01818) fell 5.83%, with a trading turnover 1.7 Billion HKD, and a year-to-date rose 6.1%. GIGADEVICE(03986) fell 3.82%, with a trading turnover 252.3 Million HKD, and a year-to-date rose 86.4%.

- The Hang Seng Index increased by 0.58%, with a year-to-date rise of 6.1%.  
- The Hang Seng Tech Index rose 0.62%, but has declined 1.2% for the year.  
- Stocks like Zhihua (02513) surged by 14.81% and recorded a significant yearly gain of 173.5%, while stocks like Zhaojin Mining (01818) dropped by 5.83% despite a yearly increase of 6.1%.

Top Gainers & Losers

DONGFANG ELEC

CSPC PHARMA

INNOVENT BIO

POP MART

ZHAOJIN MINING

GIGADEVICE

EASTROC

CTG DUTY-FREE

MEITUAN

Top 5 HK Stock Gainers/Losers (>100B) (2.10)

562050

513120

00HSI

STECH

The Hang Seng Index closed at 27,183 points, up 155 points or 0.6%; the Hang Seng TECH Index reported 5,451 points, up 33 points or 0.6%. The total market turnover was HKD 234.04 billion. Among the actively traded blue-chip stocks, CSPC PHARMA rose over 5%, ZTO EXPRESS, WH GROUP, Bank of China (Hong Kong), Wharf Real Estate Investment, and HANG LUNG PPT all reached new highs

AASTOCKS

China Universal CNI HK Connect Innovative Drugs Industry ETF

Yinhua CSI Interior Real Estate Theme ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

ZTO EXPRESS-W

ChinaAMC CSI All Share Real Estate ETF

Bosera Hang Seng Health Care ETF(QDII)

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Hwabao WP CSI Pharmaceuticals ETF

HANG LUNG PPT

Fullgoal CSI Modern Logistics ETF

WH GROUP

Penghua CSI HK Connect Health Care Composite ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

Hang Seng Index

Hang Seng TECH Index

HANG LUNG GROUP

According to the "All-Day Express," the Hang Seng Index closed at 27,183 points, up 155 points; the Hang Seng TECH Index closed at 5,451 points, up 33 points. CSPC PHARMA rose over 5%, ZTO EXPRESS-W, WH GROUP, Bank of China (Hong Kong), Wharf Real Estate Investment Company, and HANG LUNG PPT reached new highs with active trading

510660

Mainland Chinese investors have increased their investments in Hong Kong-listed drug stocks, with the Hang Seng Southbound Connect Hong Kong Innovative Drug Index rising about 9% recently. CSPC Pharmaceutical Group and Sichuan Kelun-Biotech saw significant gains. Innovent Biologics announced a major collaboration with Eli Lilly worth up to $8.85 billion, enhancing its drug development process. This trend reflects a shift in how Chinese drug makers engage with global partners, as they gain more control over the development of their medicines amid a competitive pharmaceutical landscape.

南华早报

KELUN PHARMA

SKB BIO-B

Eli Lilly

E Fund Hang Seng SCHK Innovative Drug ETF

ICBCCS SSE STAR Biology and Medicine ETF

iShares US Pharma

Yinhua CSI Innovative Drugs Industry ETF

Penghua SSE STAR Biology and Medicine ETF

ChinaAMC CSI Biotechnology Theme ETF

Huaan Hang Seng Biotech ETF

China Southern Hang Seng Biotech ETF(QDII)

Guotai CSI Hugangshen Innovative Drugs Industry ETF

Tibet Dongcai CSI Hugangshen Innovative Drugs Industry ETF

E Fund CSI Biotechnology Theme ETF

Ping An CSI Medicine and Medical Device Innovation ETF

ICBCCS CNI HK Connect Innovative Drugs ETF

Guotai SSE STAR Brand Name Drug ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Tianhong CNI BIOMEDICINE ETF

China Merchants CSI Biotechnology Theme ETF

E Fund CSI 300 Health Care ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Guotai CSI Bio-medicine ETF

Yinhua CNI HK Connect Innovative Drugs ETF

ChinaAMC SSE STAR Biology and Medicine ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Bosera Hang Seng SCHK Innovative Drug Select ETF

Mainland China’s investors pour into Hong Kong-listed drug stocks

02269

08189

01177

08037

02509

The Hang Seng Biotechnology Index rose over 4% intraday, CSPC PHARMA rose over 7%, INNOVENT BIO rose nearly 7%, WUXI BIO and SINO BIOPHARM rose over 5%

Wallstreetcn

WUXI BIO

TEDA BIOMEDICAL

SINO BIOPHARM

CH BIOTECH SER

QYUNS-B

HSBC's research report indicates that CSPC PHARMA has reached a $18.5 billion research and licensing cooperation agreement with AstraZeneca, which is expected to bring significant revenue growth. The bank has raised its revenue forecast for CSPC PHARMA for 2025 to 2027 by 3% to 11%, and its net profit forecast by 7% to 18%. HSBC maintains a "Buy" rating, raising the target price from 9 yuan to 11 yuan

HSBC Research raises CSPC Pharma's revenue and earnings forecast, target price adjusted to HKD 11

00100

02259

00670

06886

01024

09888

00700

09626

MINIMAX-WP(00100) rose 10.98%, with a trading turnover 1.1 Billion HKD, and a year-to-date rose 252.1%. KNOWLEDGE ATLAS(02513) rose 8.28%, with a trading turnover 616.0 Million HKD, and a year-to-date rose 109.3%. HTSC(06886) fell 8.24%, with a trading turnover 1.6 Billion HKD, and a year-to-date fell 10%. KUAISHOU-W(01024) fell 4.61%, with a trading turnover 5.1 Billion HKD, and a year-to-date rose 14.9%.

- The Hang Seng Index rose by 0.22% with a year-to-date increase of 4.7%, while the Hang Seng Tech Index fell by 1.07%, resulting in a decline of 0.9% year-to-date.  
- MINIMAX-WP (00100) increased by 10.98%, recording a transaction value of 1.05 billion HKD and a remarkable annual rise of 252.1%.  
- Zhihu (02513) gained 8.28%, with a transaction value of 620 million HKD and a year-to-date increase of 109.3%, while Huatai Securities (06886) dropped by 8.24%.

MINIMAX-WP

ZIJIN GOLD INTL

CHINA EAST AIR

HTSC

KUAISHOU-W

BIDU-SW

TENCENT

BILIBILI-W

Top 5 HK Stock Gainers/Losers (>100B) (2.3)

Huatai Securities has reaffirmed a Buy rating on CSPC Pharmaceutical Group (CHJTF), setting a price target of HK$19.25, while the stock closed at HK$9.15. The analyst consensus is a Moderate Buy with an average price target of HK$11.56, indicating a 26.33% upside. Additionally, CMB International Securities also maintains a Buy rating with a price target of HK$13.93.

Tip Ranks

Huatai Securities Reaffirms Their Buy Rating on CSPC Pharmaceutical Group (CHJTF)

07500

03033

07200

TCEHY

TCTZF

The Hang Seng Index opened 220 points higher this morning, but the gains narrowed later, with a minimum drop of 344 points. It ultimately closed at 26,830 points, up 54 points or 0.2%. The Tech Index reported 5,453 points at noon, down 72 points or 1.32%. CSPC PHARMA was approved to conduct clinical trials, with its stock price rising 4.15%. Internet stocks such as Kuaishou, Baidu, and Tencent fell by 4.35%, 3.54%, and 3.09% respectively. Commercial aerospace stocks rose collectively, with JunDa rising by as much as 12.95%. The three major U.S. stock indices rebounded, easing panic sentiment

- The Hang Seng Index opened 220 points higher but fluctuated, closing at 26,830 points, up 54 points or 0.2%, with a half-day turnover of 195.2 billion HKD.  
- The approval of Clinical Trials for the CAR-T product SYS6055 by China’s National Medical Products Administration boosted the share price of Hong Kong-listed Sino Biopharmaceutical by 4.15%.  
- In contrast, internet stocks like Kuaishou, Baidu, and Tencent fell sharply following news of potential VAT increases, with Tencent dragging the Hang Seng Index down by 62 points.

Stheadline

FI2 CSOP HSI

CSOP HS TECH

FL2 CSOP HSI

Tencent

Tencent Holdings Limited

The Hang Seng Index rose 54 points in the half-day session, tech stocks collectively plummeted, aerospace stocks surged, and Tencent dragged down 62 points | Hong Kong stock market midday

CMB International has raised the target price of CSPC PHARMA to RMB 13.93, maintaining a "Buy" rating. The report indicates that CSPC has signed a strategic cooperation agreement with AstraZeneca, expected to receive a USD 1.2 billion upfront payment and up to USD 17.3 billion in potential milestone payments. The company has signed 6 business expansion agreements, with sales slightly recovering in the third quarter of last year, and core revenue growing 4.2% quarter-on-quarter. BD transactions will continue to drive profit growth and support dividends

CITIC International raised the target price of CSPC PHARMA to 13.93 yuan, expecting BD transactions to support profits and dividends

300765

CSPC Pharmaceutical Group has received drug registration approval in mainland China for its fast-acting intravenous antihypertensive drug, Clevidipine Injectable Emulsion. This drug is designed for patients whose hypertension is not effectively managed with oral therapy, offering rapid blood pressure control without the need for dose adjustments. The approval enhances CSPC's cardiovascular product pipeline and addresses the demand for acute-care hypertension treatments in Chinese hospitals. Analysts rate the stock as a Buy with a price target of HK$10.50.

CSPC Innovation

CSPC Wins China Approval for Fast-Acting Intravenous Hypertension Drug

CSPC Pharmaceutical Group Limited has received drug registration approval from China's National Medical Products Administration for its Clevidipine Injectable Emulsion, indicated for hypertension treatment when oral therapy is not feasible. The product offers rapid action, requires no dose adjustment for hepatic or renal dysfunction, and can be administered without dilution, making it suitable for patients at risk of fluid overload. This approval is expected to enhance the company's cardiovascular product pipeline.

Reuters

CSPC Pharmaceutical Group Receives Approval for Clevidipine Injectable Emulsion

AstraZeneca has entered a licensing agreement with China's CSPC Pharmaceutical for weight-loss drugs, valued at up to $18.5 billion. The UK-based company will pay $1.2 billion upfront and potentially $17.3 billion more based on milestones. Additionally, AstraZeneca plans to invest $15 billion in China over the next five years for manufacturing and R&D. Following the announcement, CSPC's shares dropped 10.2%, while AstraZeneca's stock rose 1%.

AstraZeneca

AstraZeneca escalates Big Pharma’s China land grab

Hot trading industry trends on August 7 and related Hong Kong semiconductor stocks. Hong Kong semiconductor stocks opened lower in early trading but then surged strongly, with Innoscience gaining over 11%, and industry leader SMIC rising over 3%. Core logic: On the news front, on August 1, Innoscience officially responded to rumors of collaboration with NVIDIA. The announcement stated that the company has recently partnered with global AI technology leader NVIDIA to jointly promote the large-scale implementation of the 800VDC (800-volt direct current) power architecture in AI data centers. Clear signals of a cyclical bottom: Global semiconductor inventory reduction is nearing its end...

NVIDIA

SMIC

SMIC HK SDR 5to1

SJM HOLDINGS

MGM CHINA

FIT HON TENG

WUXI APPTEC

WuXi AppTec

INNOCARE

InnoCare Pharma

XIAOMI-W

XIAOMI-WR

Xiaomi HK SDR 2to1

Xiaomi Corporation

GALAXY ENT

Galaxy Entertainment Group

NAGACORP

WYNN MACAU

MELCO INT'L DEV

SANDS CHINA LTD

Sands China

COWELL

HUA HONG SEMI

Hua Hong

SHANGHAI FUDAN

FMSH

INNOSCIENCE

SOLOMON SYSTECH

TIGERMED

Tigermed

Hot Trades in Hong Kong Stocks (8.7)｜ Chip Stocks Rebound Strongly, Apple Supply Chain Follows; Xiaomi and Pharmaceuticals Retreat Under Pressure

CI-CSPC@EC2602B(19021.HK)

Top 5 HK Stock Gainers/Losers (>100B) (2.10)

Mainland China’s investors pour into Hong Kong-listed drug stocks

The Hang Seng Biotechnology Index rose over 4% intraday, CSPC PHARMA rose over 7%, INNOVENT BIO rose nearly 7%, WUXI BIO and SINO BIOPHARM rose over 5%

HSBC Research raises CSPC Pharma's revenue and earnings forecast, target price adjusted to HKD 11